Volume 14 Supplement 2

6th European Symposium: Steps Forward in Pompe Disease

Open Access

Three years experience with dried blood spot α-glucosidase screening for Pompe disease in British Columbia, Canada

  • Gabriella Horvath1,
  • Sandra Sirrs1,
  • Sylvia Stockler1,
  • Ramona Salvarinova-Zivkovic1,
  • Hilary Vallance1 and
  • Paula Waters1
BMC Musculoskeletal Disorders201314(Suppl 2):P2

https://doi.org/10.1186/1471-2474-14-S2-P2

Published: 29 May 2013

Introduction

Pompe disease (OMIM #232300) or glycogen storage disease type II is an autosomal recessive lysosomal storage disease caused by mutations in the glucosidase alpha acid (GAA) gene. The acid alpha-glucosidase enzyme is required for the degradation of cellular glycogen, and its reduced activity results in accumulation of glycogen in muscle and cardiac tissues with variable clinical presentation. Demonstration of deficient acid alpha-glucosidase (GAA) enzyme activity is diagnostic, and molecular testing is available for confirmation or clarification. As Pompe disease is in the differential diagnosis of a wide variety of myopathies, simple first-line tests are needed. Use of dried blood spots (DBS) has logistical advantages over the traditional approach of enzyme assay in isolated lymphocytes, and enzyme stability permits DBS shipment to a central laboratory.

Methods/results

Patients were referred for enzyme testing who presented with muscle weakness, muscle pain, respiratory insufficiency, and/or cardiomyopathy in infancy. Dried blood spot (DBS) acid α-glucosidase testing, with neutral α-glucosidase as a control enzyme, was measured using a previously described fluorimetric method [1, 2]. Out of 149 samples tested, three cases of Pompe disease were detected by DBS assay during a three year period. Two patients with low values for acid α-glucosidase in DBS were confirmed to carry hypomorphic alleles not associated with clinical disease. Two patients with low values, overlapping those of the two patients with hypomorphic alleles, had no mutations detected. Two further patients had normal results on a second DBS card, suggesting that the initial blood spots might have been compromised.

Conclusion

Since the introduction of the DBS alpha-glucosidase method, several new Pompe cases have been diagnosed at our centre. A repeat DBS should be requested to confirm initial low results before proceeding to further testing. In a significant proportion of false positive cases, benign hypomorphic alleles provide an explanation for reduced activity of acid α-glucosidase.

Authors’ Affiliations

(1)
British Columbia Children's Hospital

References

  1. Kallwass H, Carr C, Gerein J, Titlow M, Pomponio R, Bali D, Dai J, Kishnani P, Skrinar A, Corzo D, Keutzer J: Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots. Mol Genet Metab. 2007, 90: 449-452. 10.1016/j.ymgme.2006.12.006.View ArticlePubMedGoogle Scholar
  2. Goldstein J, Young S, Changela M, Dickerson G, Zhang H, Dai J, Peterson D, Millington D, Kishnani P, Bali D: Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Muscle Nerve. 2009, 40: 32-36. 10.1002/mus.21376.View ArticlePubMedGoogle Scholar

Copyright

© Horvath et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement